FOLH1 and prostate cancer: However, despite its high specificity, PSMA PET/CT has a moderate to low sensitivity of 40–50% for pelvic lymph node detection [5–7], implicating that a negative PSMA PET/CT cannot rule out lymph node metastases and that for adequate prostate cancer staging an ePLND is still needed.